Dec 18, 2025, 08:00 ET CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways 1,2 In the REDEFINE 1 phase 3 trial, adults with obesity, or overweight with at least one obesity-related complication, taking CagriSema lost an average of 23% body weight when evaluating the treatment effect if all patients stayed on treatment *2 Novo Nordisk continues to build on its 100-year-plus legacy of science and innovation, with potential new treatments in obesity PLAINSBORO, N.J
Attending Surgeon Director, Head & Neck Oncologic Surgery Fellowship Program Head, Laboratory of Experimental Cancer Immunogenomics Conditions I Treat Head and neck cancers Thyroid cancer and conditions Salivary gland tumors Mouth (oral) cancers and conditions Skin cancer and conditions Throat cancers and conditions Laryngeal (larynx) cancer Melanoma Subglottic stenosis My Specialties Surgery Education MD, New York University School of Medicine MSc, Columbia University Residencies Head and Neck Surgery, New York University Medical Center Fellowships Head and Neck Surgical Oncology, Memorial Sloan Kettering Cancer Center Cancer Genomics, Memorial Sloan Kettering Cancer Center Board Certifications Otolaryngology Head and Neck Surgery Awards and Honors Castle Connolly: Americas Top Doctor (2026) Castle Connolly: Americas Top Doctor (2025) Castle Connolly: Americas Top Doctor (2024) Castle Connolly: Top Doctors New York Metro Area (2023) Castle Connolly: America's Top Doctors (2023) Castle Connolly: New York Magazine Top Doctors (2018-2023) Catherine and Frederick Adler Junior Faculty Endowed Chair (20142019) Elected Member, American Society for Clinical Investigation Elected Fellow, Triological Society Translational Innovator Award, American Head and Neck Society Clinical Investigator Award, Damon Runyon Cancer Research Foundation Insurance Information Understanding your insurance options is an important part of managing your cancer care
PMC 1136115
Q: Can I get pharmaceutical versions
